Zapaq Overview
- Year Founded
-
2000
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
Zapaq General Information
Description
Operator of a bio pharmaceutical company. The company focuses research on the development of drugs that inhibit a key enzyme involved in the production of beta-amyloid.
Contact Information
Corporate Office
- 1050 Winter Street
- Suite 1000
- Waltham, MA 02451
- United States
Corporate Office
- 1050 Winter Street
- Suite 1000
- Waltham, MA 02451
- United States
Zapaq Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 14-Aug-2006 | Completed | Clinical Trials - General | |||
| 3. Early Stage VC (Series B) | 20-Sep-2005 | Completed | Startup | |||
| 2. Early Stage VC (Series A2) | 18-Mar-2004 | $6.02M | $11.2M | Completed | Startup | |
| 1. Early Stage VC (Series A1) | 01-Mar-2004 | $5.16M | $5.16M | Completed | Startup |
Zapaq Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A2 | ||||||||
| Series A1 | 570,561 | $0.001000 | 8% | $2 | $2 | $2 | 1.47% |
Zapaq Patents
Zapaq Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20070117793-A1 | E.g. n1-(4-(3-(fluoromethyl)benzylamino)-3-hydroxy-1-phenylbutan-2-yl)-n3-methyl-n3-((4-methylthiazol-2-yl)methyl)isophthalamide;2 beta-secretase inhibitor; decrease hydrolysis of a beta -secretase site of a memapsin 2 substrate; alzheimer's disease | Active | 08-Apr-2005 | ||
| US-20050239684-A1 | Selectively inhibit memapsin 2 beta -secretase activity relative to memapsin 1 beta -secretase activity; alzheimer's disease | Active | 23-Oct-2001 | ||
| US-20060234944-A1 | Selectively inhibit memapsin 2 beta -secretase activity relative to memapsin 1 beta -secretase activity; alzheimer's disease | Inactive | 23-Oct-2001 | C07K7/06 |
Zapaq Former Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Astellas Venture Management | Corporate Venture Capital | Minority | ||
| Oklahoma Life Science Fund | Venture Capital | Minority | ||
| Sanderling Ventures | Venture Capital | Minority | ||
| The Estée Lauder Companies | Corporation | Minority |
Zapaq FAQs
-
When was Zapaq founded?
Zapaq was founded in 2000.
-
Where is Zapaq headquartered?
Zapaq is headquartered in Waltham, MA.
-
What industry is Zapaq in?
Zapaq’s primary industry is Drug Discovery.
-
Is Zapaq a private or public company?
Zapaq is a Private company.
-
What is Zapaq’s current revenue?
The current revenue for Zapaq is .
-
How much funding has Zapaq raised over time?
Zapaq has raised $17.9M.
-
Who are Zapaq’s investors?
Astellas Venture Management, Oklahoma Life Science Fund, Sanderling Ventures, and The Estée Lauder Companies have invested in Zapaq.
-
When was Zapaq acquired?
Zapaq was acquired on 14-Aug-2006.
-
Who acquired Zapaq?
Zapaq was acquired by CoMentis (Drug Discovery).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process